PortViewPortView
Curis logo

Curis (CRIS) Stock Analysis

NASDAQHealthcareBiotechnology

$1.41-0.90%
1-year price historyRange $1.40 – $36.40
52-week range$1.41
$1.40$39.00

What Curis does

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Key metrics

Market cap
$2.74M
P/E (TTM)
-0.90
EPS (TTM)
$-1.57
Beta
3.09
Dividend yield
0.00%
Revenue / share
$2.02
50-day avg
$4.21
200-day avg
$13.59
52-week high
$39.00
52-week low
$1.40
CEO
James Dentzer

ETFs linked to CRIS

Broad-market and Healthcare sector ETFs an investor holding Curis is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CRIS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CRIS in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Curis?
Curis trades under the ticker CRIS on NASDAQ.
Which exchange is CRIS listed on?
CRIS is listed on NASDAQ.
What sector does Curis operate in?
Curis is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze CRIS in a portfolio?
PortView shows CRIS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.